



13th February, 2026

The Dy. General Manager (Listing Dept.)
BSE Limited,
Corporate Relationship Dept.,
1st Floor, New Trading Ring,
P. J. Towers, Dalal Street, Fort,
Mumbai - 400 001
(BSE Scrip Code: 500420)

The Manager – Listing Dept.,
National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G. Block,
Bandra - Kurla Complex, Bandra (E),
Mumbai – 400 051
(NSE Scrip Code: TORNTPHARM)

Dear Sir,

Sub.: Presentation to analysts on unaudited Consolidated Financial Results for the quarter and nine months ended 31st December, 2025

The Presentation on unaudited Consolidated Financial Results for the quarter and nine months ended 31st December, 2025 to be made to analysts is enclosed for your records.

Thanking you,

Yours sincerely,

For TORRENT PHARMACEUTICALS LIMITED

CHINTAN M. TRIVEDI
COMPANY SECRETARY

Encl : A/a

TORRENT PHARMACEUTICALS LIMITED

CIN : L24230GJ1972PLC002126

Regd. Office: Avirat, Thaltej Shilaj Road, Ahmedabad – 380059

Phone: +91 79 26599000, Fax : +91 79 26582100, www.torrentpharma.com

Email – investorservices@torrentpharma.com

Revenue: Summary

Q3 FY 2025-26

Revenue: Summary

Revenues (Rs cr)	Q3 FY26	Q3 FY25	Gr%
India	1798	1581	14%
United States	321	271	19%
Germany	304	282	8%
Brazil	371	291	27%
Others	509	384	32%
Total	3303	2809	18%

Revenue: Summary

Revenues (Rs cr)	YTD Dec 25	YTD Dec 24	Gr%
India	5430	4848	12%
United States	967	798	21%
Germany	916	853	7%
Brazil	907	750	21%
Others	1563	1308	20%
Total	9783	8557	14%